Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Mutated Melanoma”

129 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 129 results

Not applicableStudy completedNCT04039672
What this trial is testing

Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma

Who this might be right for
Melanoma
Hospices Civils de Lyon 10
Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Not applicableStudy completedNCT03139513
What this trial is testing

Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Who this might be right for
Melanoma
Hoffmann-La Roche 200
Early research (Phase 1)Study completedNCT01351103
What this trial is testing

LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Who this might be right for
Pancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more
Novartis Pharmaceuticals 185
Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Study completedNCT02039947
What this trial is testing

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Who this might be right for
Melanoma and Brain Metastases
Novartis Pharmaceuticals 127
Not applicableLooking for participantsNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Early research (Phase 1)Study completedNCT02608034
What this trial is testing

Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Genentech, Inc. 32
Not applicableStudy completedNCT02663232
What this trial is testing

Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Who this might be right for
Metastatic Cancers
Hoffmann-La Roche 264
Testing effectiveness (Phase 2)Active Not RecruitingNCT04074096
What this trial is testing

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Who this might be right for
Malignant MelanomaBRAF V600 MutationBrain Metastases
UNICANCER 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05275374
What this trial is testing

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Who this might be right for
CancerBRAF V600 MutationMelanoma+3 more
Xynomic Pharmaceuticals, Inc. 221
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Ended earlyNCT01562899
What this trial is testing

MEK162 and AMG 479 in Patients With Selected Solid Tumors

Who this might be right for
Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma
Pfizer 77
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Load More Results